JP2002527101A - ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進 - Google Patents

ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進

Info

Publication number
JP2002527101A
JP2002527101A JP2000577279A JP2000577279A JP2002527101A JP 2002527101 A JP2002527101 A JP 2002527101A JP 2000577279 A JP2000577279 A JP 2000577279A JP 2000577279 A JP2000577279 A JP 2000577279A JP 2002527101 A JP2002527101 A JP 2002527101A
Authority
JP
Japan
Prior art keywords
cells
stem cells
hematopoietic
histone deacetylase
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000577279A
Other languages
English (en)
Japanese (ja)
Inventor
ラヴァウ・カテリーヌ・ピー
ヤング・ジュディ・キャロル
ヒル・ベス・ルイーズ
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2002527101A publication Critical patent/JP2002527101A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000577279A 1998-10-16 1999-10-14 ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進 Pending JP2002527101A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17363398A 1998-10-16 1998-10-16
US09/173,633 1998-10-16
US13247699P 1999-05-04 1999-05-04
US60/132,476 1999-05-04
PCT/EP1999/007741 WO2000023567A2 (fr) 1998-10-16 1999-10-14 Procede pour favoriser l'autorenouvellement et transduction genique amelioree des cellules souches hematopoietiques par des inhibiteurs de desacetylase de l'histone

Publications (1)

Publication Number Publication Date
JP2002527101A true JP2002527101A (ja) 2002-08-27

Family

ID=26830391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000577279A Pending JP2002527101A (ja) 1998-10-16 1999-10-14 ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進

Country Status (5)

Country Link
EP (1) EP1129175A2 (fr)
JP (1) JP2002527101A (fr)
AU (1) AU6339399A (fr)
CA (1) CA2346152A1 (fr)
WO (1) WO2000023567A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013146480A1 (fr) * 2012-03-29 2013-10-03 タカラバイオ株式会社 Procédé d'introduction de gène
JP2015216853A (ja) * 2014-05-14 2015-12-07 国立大学法人京都大学 巨核球前駆細胞の製造方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032669A (en) * 1990-05-01 1991-07-16 University Of Massachusetts At Amherst Liquid crystalline polyesters formed by reaction of bis(hydroxyalkoxy) biphenyls with terephthaloyl chloride
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
DE10162080A1 (de) * 2001-12-10 2003-06-26 Albrecht Mueller Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential
IL163875A0 (en) 2002-03-07 2005-12-18 Univ Delaware Methods, compositions, and kits for enhancing oli gonucleotide mediated nucleic acid sequence alteration using compositions comprising a histone de
EP1593737B1 (fr) * 2004-05-05 2011-02-02 Zorica Becker-Kojic Utilisation d'anticorps contre la glycoprotéine ACA pour l'obtention ou le maintien de cellules souches pluripotentes non-embryonnaires
ATE527341T1 (de) * 2004-10-27 2011-10-15 Univ Bruxelles Hepatische differenzierung von stammzellen
AU2006270322A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN103113463B (zh) 2005-12-13 2015-02-18 国立大学法人京都大学 核重新编程因子
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
JP5346925B2 (ja) 2008-05-02 2013-11-20 国立大学法人京都大学 核初期化方法
EP2612909B1 (fr) 2010-10-05 2015-02-25 Takara Bio, Inc. Procédé de production d'un vecteur viral
KR102011532B1 (ko) 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. 개선된 바이러스 형질도입을 위한 화합물
US9399780B2 (en) 2012-03-22 2016-07-26 Takara Bio Inc. Method for producing viral vector
KR102097191B1 (ko) * 2016-11-10 2020-04-06 울산대학교 산학협력단 히스톤 탈아세틸화 저해제 및 프라이밍 인자를 유효성분으로 포함하는 줄기세포 활성 촉진용 조성물
WO2018088821A1 (fr) * 2016-11-10 2018-05-17 울산대학교 산학협력단 Composition favorisant l'activité des cellules souches, comprenant un inhibiteur d'histone désacétylase et un facteur d'amorçage en tant que principes actifs
WO2021207673A1 (fr) * 2020-04-09 2021-10-14 The Regents of the University of Colorodo, a body corporate Compositions, méthodes et utilisations pour production de cellules souches hématopoïétiques (csh)
US20230193212A1 (en) 2020-05-06 2023-06-22 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314644A (en) * 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
EP0827742A1 (fr) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Utilisation des inhibiteurs de l'histone déacétylase pour le traitement de la fibrose ou de la cirrhose

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013146480A1 (fr) * 2012-03-29 2013-10-03 タカラバイオ株式会社 Procédé d'introduction de gène
JP2015216853A (ja) * 2014-05-14 2015-12-07 国立大学法人京都大学 巨核球前駆細胞の製造方法

Also Published As

Publication number Publication date
EP1129175A2 (fr) 2001-09-05
WO2000023567A3 (fr) 2000-07-27
AU6339399A (en) 2000-05-08
WO2000023567A2 (fr) 2000-04-27
CA2346152A1 (fr) 2000-04-27

Similar Documents

Publication Publication Date Title
JP2002527101A (ja) ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進
US7416887B2 (en) Methods for use of MPL ligands with primitive human stem cells
US8609411B2 (en) Ex vivo expansion of human hematopoietic stem cells
CA2912688C (fr) Cellules souches enrichies et expansees de sang de cordon humain pour traitement de troubles hematologiques
US20190345450A1 (en) Strategies to assess and/or produce cell populations with predictive engraftment potential
Gori et al. Endothelial cells promote expansion of long-term engrafting marrow hematopoietic stem and progenitor cells in primates
KR20160075676A (ko) 방법
US5837507A (en) Hox-induced enhancement of in vivo and in vitro proliferative capacity and gene therapeutic methods
JP2002502599A (ja) 増殖され遺伝子的に修飾されたヒト造血幹細胞集団
Zhang et al. Effects of HOXB4 overexpression on ex vivo expansion and immortalization of hematopoietic cells from different species
JP2005538720A (ja) 哺乳動物巨核球前駆細胞
Barcia Durán et al. Endothelial Jak3 expression enhances pro-hematopoietic angiocrine function in mice
AU728557B2 (en) Hematopoietic stem cells and methods for generating such cells
US20230212516A1 (en) Methods for expanding hematopoietic stem cells
JPWO2005056778A1 (ja) 造血幹細胞の分化抑制又は増殖方法
US20230159895A1 (en) Strategies to assess and/or produce cell populations with predictive engraftment potential
Dalby Forward programming of human pluripotent stem cells to a megakaryocyte-erythrocyte bi-potent progenitor population: an in vitro system for the production of platelets and red blood cells for transfusion medicine.
US20100209396A1 (en) Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells
EP1361268A1 (fr) Cellules pro-B deficientes pour Pax-5, méthodes pour leur production et pour leur utilisation en thérapie humaine
WO2024077153A1 (fr) Mégacaryocytes et plaquettes dérivés de cellules souches pluripotentes
JP2005514071A (ja) 内皮細胞との前培養による遺伝子導入効率の上昇
Nolta et al. Human hematopoietic cell culture, transduction, and analyses
Chu Effect of c-kit and flt-3 overexpression on primitive hematopoietic cells
Pan Functional studies of transcription factors GATA-1, Fli-1 and FOG-1 in Megakaryocyte development.
Conneally Genetic modification of human hematopoietic stem cells

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20041026